Toggle menu

BreathSpec study

Start date:
December 2018
End date:
April 2019
Co-ordinated by:
Julia Grahamslaw
Main trial site:
Liverpool School of Tropical Medicine

A multicentre prospective, observational, longitudinal cohort study in adult patients with suspected upper or lower respiratory infection (URTI/LRTI) to identify a spectrum of biomarkers in exhaled breath to discriminate participants with bacterial RTI from participants without.

Identification of chemical biomarkers in exhaled breath that potentially discriminates participants with bacterial RTI from participants without.

Additional endpoints explored will be variations of the chemical spectrum from all participants using a portable GC-IMS device (Breathspec) stratified by confounding factors, such as (but not limited to) gender, age, antibiotic therapy and smoking status.

 

Local PI

Dr Matt Reed

Director of EMERGE, Consultant, NRS Career Research Fellow & Honorary Reader in Emergency Medicine

Research Team

Fiona McCurrach

Senior Research Nurse

Julia Grahamslaw

Lead Research Nurse

Alison Williams

Senior Research Nurse

Clare Moceivei

Research Nurse- Bank Staff

Caroline Blackstock

AMU Senior Research Nurse

Sian Dalgleish

Senior Research Nurse

Dr Adam Lloyd

Honorary Research Fellow & Lecturer

Emma Moatt

Research Project Manager

More EMERGE Trials

DASH Trial

DASH is a randomised clinical trial investigating a treatment to reverse the effects of blood-thinning medications.

Assisting in identifying patients with Humeral shaft fractures in the ED by screening.

Giving patient information sheets to introduce the study, so patient has had adequate time to read and make decision about going into the trial before going to the fracture clinic.

Read more

HU-FIX Trial

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study